Eosinophilic Esophagitis - A Pipeline Analysis Report

Overview of the drug development for eosinophilic esophagitis

Eosinophilic esophagitis is a chronic immune-mediated disorder of the esophagus that affects individuals of all age groups including both adults and children. This disorder is also known as asthma of the esophagus. Patients suffering from this condition are diagnosed with a large number of white blood cells in the tissues of the esophagus. These white blood cells are known as eosinophils. Factors such as the damage to the esophagus, multiplication of eosinophils, and reaction of the esophagus can result in eosinophilic esophagitis disorder. Technavio’s market research analysts have predicted that with the introduction of dietary therapy, proton pump inhibitor (PPI), and topical steroid as some of the most promising investigational approaches to treat eosinophilic esophagitis, the eosinophilic esophagitis market size, and share will increase in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that almost the same amount of drug molecules comes under the phase II drug development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the pre-registration and phase III stage.

Companies covered

This pipeline analysis report mentions the eosinophilic esophagitis market opportunity and provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of eosinophilic esophagitis. In addition to providing information on the various stages of molecules developed by companies for different drug development landscape, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Adare Pharmaceuticals
• Biotica Pharmaceuticals
• Calypso Biotech

Drug development strategies of the drug development for eosinophilic esophagitis by route of administration

• Intravenous and subcutaneous
• Oral
• Subcutaneous

The oral route of administration (ROA) involves the administration of drugs through a mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.

Drug development strategies of the drug development for eosinophilic esophagitis for therapeutic modalities

• Monoclonal antibodies
• Small molecules

According to this pipeline analysis report, some of the molecules that are currently in the drug development pipeline for eosinophilic esophagitis are being developed as monoclonal antibodies. Monoclonal antibodies bind to only one substance in the body as they are made by identical immune cells that are all clones of a unique parent cell.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for eosinophilic esophagitis?
• What are the companies that are currently involved in the development of drug development molecules for eosinophilic esophagitis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.